Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7562506rdf:typepubmed:Citationlld:pubmed
pubmed-article:7562506lifeskim:mentionsumls-concept:C0023779lld:lifeskim
pubmed-article:7562506lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:7562506lifeskim:mentionsumls-concept:C0333348lld:lifeskim
pubmed-article:7562506lifeskim:mentionsumls-concept:C0033268lld:lifeskim
pubmed-article:7562506lifeskim:mentionsumls-concept:C0243077lld:lifeskim
pubmed-article:7562506lifeskim:mentionsumls-concept:C0127400lld:lifeskim
pubmed-article:7562506lifeskim:mentionsumls-concept:C0052296lld:lifeskim
pubmed-article:7562506lifeskim:mentionsumls-concept:C1363844lld:lifeskim
pubmed-article:7562506pubmed:issue3lld:pubmed
pubmed-article:7562506pubmed:dateCreated1995-10-25lld:pubmed
pubmed-article:7562506pubmed:abstractTextThe enzyme CoA-independent transacylase (CoA-IT) has been proposed to mediate the movement of arachidonate between specific phospholipid subclasses, and we have shown that two inhibitors of CoA-IT (SK&F 98625 and SK&F 45905) block this movement. In this report, we use these inhibitors to further characterize the role of CoA-IT in the production of lipid mediators. SK&F 98625 (diethyl 7-(3,4,5-triphenyl-2-oxo-2,3-dihydro-imidazol-1-yl)heptane- phosphonate) and SK&F 45905 [2(-)[3-(4-chloro-3-trifluoromethylphenyl)ureido]-4-trifluoromethyl phenoxy]-4,5-dichlorobenzenesulfonic acid) inhibited CoA-IT activity (IC50 values of 9 microM and 6 microM, respectively). Neither compound had any effect on cyclooxygenase, 14-kDa PLA2 or acetyltransferase activities at concentrations below 20 microM. However, SK&F 45905 inhibited 85-kDa PLA2 activity (IC50 = 3 microM), and both compounds inhibited 5-lipoxygenase activity (IC50 values of 2-4 microM). In ionophore-stimulated neurotrophils, SK&F 98625 and SK&F 45905 blocked the liberation of arachidonic acid from phospholipids, which suggests that the movement of arachidonate into specific phospholipid pools is a prerequisite for release. Both compounds also inhibited the production of platelet-activating factor in ionophore-stimulated neutrophils and antigen-stimulated mast cells. This inhibition of platelet-activating factor and arachidonic acid release was not mimicked by an inhibitor of 5-lipoxygenase, zileuton, which indicates that the primary mode of action of SK&F 98625 and SK&F 45905 is via inhibition of CoA-IT. SK&F 98625 and SK&F 45905 were able to decrease prostaglandin production in several inflammatory cells and to block signs of inflammation in ears of phorbol ester-challenged mice. Taken together, these results show that blockade of CoA-IT, which leads to inhibition of arachidonate remodelling between phospholipids, results in the attenuation of platelet-activating factor production, arachidonic acid release and the formation of eicosanoid products.lld:pubmed
pubmed-article:7562506pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7562506pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7562506pubmed:languageenglld:pubmed
pubmed-article:7562506pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7562506pubmed:citationSubsetIMlld:pubmed
pubmed-article:7562506pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7562506pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7562506pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7562506pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7562506pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7562506pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7562506pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7562506pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7562506pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7562506pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7562506pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7562506pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7562506pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7562506pubmed:statusMEDLINElld:pubmed
pubmed-article:7562506pubmed:monthSeplld:pubmed
pubmed-article:7562506pubmed:issn0022-3565lld:pubmed
pubmed-article:7562506pubmed:authorpubmed-author:WinklerJ DJDlld:pubmed
pubmed-article:7562506pubmed:authorpubmed-author:GriswoldDDlld:pubmed
pubmed-article:7562506pubmed:authorpubmed-author:MarshallL ALAlld:pubmed
pubmed-article:7562506pubmed:authorpubmed-author:ChiltonF HFHlld:pubmed
pubmed-article:7562506pubmed:authorpubmed-author:SHIHY FYFlld:pubmed
pubmed-article:7562506pubmed:authorpubmed-author:NixonA BABlld:pubmed
pubmed-article:7562506pubmed:authorpubmed-author:FontehA NANlld:pubmed
pubmed-article:7562506pubmed:authorpubmed-author:Chabot-Fletch...lld:pubmed
pubmed-article:7562506pubmed:authorpubmed-author:HeraviJ DJDlld:pubmed
pubmed-article:7562506pubmed:issnTypePrintlld:pubmed
pubmed-article:7562506pubmed:volume274lld:pubmed
pubmed-article:7562506pubmed:ownerNLMlld:pubmed
pubmed-article:7562506pubmed:authorsCompleteYlld:pubmed
pubmed-article:7562506pubmed:pagination1338-47lld:pubmed
pubmed-article:7562506pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:7562506pubmed:meshHeadingpubmed-meshheading:7562506-...lld:pubmed
pubmed-article:7562506pubmed:meshHeadingpubmed-meshheading:7562506-...lld:pubmed
pubmed-article:7562506pubmed:meshHeadingpubmed-meshheading:7562506-...lld:pubmed
pubmed-article:7562506pubmed:meshHeadingpubmed-meshheading:7562506-...lld:pubmed
pubmed-article:7562506pubmed:meshHeadingpubmed-meshheading:7562506-...lld:pubmed
pubmed-article:7562506pubmed:meshHeadingpubmed-meshheading:7562506-...lld:pubmed
pubmed-article:7562506pubmed:meshHeadingpubmed-meshheading:7562506-...lld:pubmed
pubmed-article:7562506pubmed:meshHeadingpubmed-meshheading:7562506-...lld:pubmed
pubmed-article:7562506pubmed:meshHeadingpubmed-meshheading:7562506-...lld:pubmed
pubmed-article:7562506pubmed:meshHeadingpubmed-meshheading:7562506-...lld:pubmed
pubmed-article:7562506pubmed:meshHeadingpubmed-meshheading:7562506-...lld:pubmed
pubmed-article:7562506pubmed:meshHeadingpubmed-meshheading:7562506-...lld:pubmed
pubmed-article:7562506pubmed:meshHeadingpubmed-meshheading:7562506-...lld:pubmed
pubmed-article:7562506pubmed:meshHeadingpubmed-meshheading:7562506-...lld:pubmed
pubmed-article:7562506pubmed:meshHeadingpubmed-meshheading:7562506-...lld:pubmed
pubmed-article:7562506pubmed:meshHeadingpubmed-meshheading:7562506-...lld:pubmed
pubmed-article:7562506pubmed:year1995lld:pubmed
pubmed-article:7562506pubmed:articleTitleEffects of CoA-independent transacylase inhibitors on the production of lipid inflammatory mediators.lld:pubmed
pubmed-article:7562506pubmed:affiliationDivision of Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania, USA.lld:pubmed
pubmed-article:7562506pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7562506pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7562506lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7562506lld:pubmed